Crown Bioscience President Dr Jean-Pierre Wery honoured in PharmaVOICE 100

Dr Jean-Pierre Wery, president of drug discovery and development service company Crown Bioscience Inc, has been selected by PharmaVOICE as one of the top 100 most inspiring people within the life sciences sector.

Dr Wery was selected from a large cross section of established professionals in the life sciences industry for his continuing contributions to improving the efficiency and reducing the cost of the drug discovery and development process via translational science platforms for oncology and metabolic disease.

Since joining Crown Bioscience in 2008, Dr Wery has developed solutions to some of the biggest problems facing drug development in oncology and metabolic disease, namely the increasing attrition rates in the clinic.

Confronting this issue, Dr Wery has pioneered a translational platform that can be easily accessed by researchers in both the oncology and metabolic disease fields. Access to this platform will have a profound impact on the overall efficiency of the drug discovery and development process, significantly bridging the gap between pre-clinical promise and successful clinical development – it has so far been used by over 300 global drug developers to date.

Dr Wery has made a unique impact in the application of one of the cornerstones of Crown’s oncology translational platform: novel animal models called Patient Derived Xenograft (PDX), which have been shown to be extremely predictive on how a human tumour will react to a given treatment. 

Dr Wery has guided Crown Bioscience to build the world’s largest and best characterized collection of such PDX models encompassing many cancer types from both Caucasian and Asian patients – a collection which reached 1,000 models in April 2014. 

The collection’s size and diversity allows for more informed preclinical decision making on prospective drug candidates, and offers pharmaceutical and biotech partners a unique tool to improve the selection and development path for promising clinical candidates. This can significantly accelerate research programs, reducing costs and failure rates of drug candidate development.

Recent Issues